COR

James F. Cleary

Known title: Chief Financial OfficerCIK: 0001333281

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.

this person other insiders at COR

Transaction History

COR▲ Buy$0
COR▼ Sell$1.9M
COR▲ Buy$3.9M
COR▼ Sell$9.3M
COR▲ Buy—
COR▼ Sell$70K
COR▼ Sell$298K
COR▲ Buy—
COR▼ Sell$4.3M
COR▲ Buy$0
COR▼ Sell$451K
COR▲ Buy—
COR▼ Sell$254K
COR▲ Buy—
COR▼ Sell$0
COR▲ Buy—
COR▼ Sell$48K
COR▲ Buy$3.0M
COR▼ Sell$5.5M
COR▲ Buy$0
COR▼ Sell$3.7M
COR▲ Buy—
COR▲ Buy—
COR▼ Sell$390K
COR▲ Buy—
COR▼ Sell$322K
COR▼ Sell$233K
COR▲ Buy—
COR▼ Sell$63K
COR▲ Buy$3.0M
COR▼ Sell$5.1M
COR▲ Buy—
COR▲ Buy—
COR▼ Sell$332K
COR▼ Sell$310K
COR▼ Sell$2.3M
COR▲ Buy—
COR▼ Sell$223K
COR▲ Buy—
COR▲ Buy$2.9M
COR▼ Sell$4.5M
COR▲ Buy—
COR▼ Sell$62K
COR▲ Buy—
COR▼ Sell$411K
COR▼ Sell$261K
COR▲ Buy—
COR▼ Sell$244K
COR▲ Buy—
COR▲ Buy—
COR▼ Sell$2.0M
COR▲ Buy—
COR▼ Sell$272K
COR▼ Sell$1.3M
COR▲ Buy—
COR▲ Buy—
COR▼ Sell$143K

We use analytics to understand how market-wall is used. No personal data is sold.